Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience

Table 1 Demographic data of the 796 patients with gastric cancer n (%)

Age (yr)	Median	58 (22-90)
Sex	Male	552 (69)
	Female	244 (31)
Median follow-up time	12 mo (range: 1-276 mo)
Median survival	12 mo (range: 11.5-12.4 mo)
Tumor location	Pyloric + antrum	362 (45.4)
	Large and small curvature	252 (31.6)
	Cardio-esophageal	97 (12.2)
	Diffuse	9 (1.1)
Stage	Stage I	29 (3.6)
	Stage II	43 (5.4)
	Stage III	195 (24.5)
	Stage IV	393 (49.3)
Type of surgery	Total gastrectomy	265 (33.2)
	Subtotal gastrectomy	174 (21.8)
	Inoperable/palliative	341 (42.8)
Treatment	Adjuvant	352 (44.2)
	Metastatic	394 (49.4)
	Untreated follow-up	50 (3.9)
Histology	Adenocarcinoma (intestinal type)	493 (61.9)
	Signet ring cell (diffuse)	254 (31.9)
	Neuroendocrine	24 (3)
	Others	8 (1.1)
In metastasis	Peritonitis carcinomatosa	193 (24.2)
	Liver	169 (21.2)
	Lymphadenopathy	73 (9.2)
	Liver + peritoneum	35 (4.4)
	Lung	28 (3.5)
	Pleural effusion + acid	24 (3)
	Bone	23 (2.9)
	Others	17 (2.1)
Recurrence in	Peritonitis carcinomatosa	61 (40.1)
	Liver	36 (23.7)
	Lymphadenopathy	24 (15.8)
	Local	14 (9.2)
	Pleural/lung	12 (7.9)
	Others	5 (5)